0001179110-16-030648.txt : 20161011 0001179110-16-030648.hdr.sgml : 20161011 20161011175823 ACCESSION NUMBER: 0001179110-16-030648 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161006 FILED AS OF DATE: 20161011 DATE AS OF CHANGE: 20161011 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kumar Ravindra CENTRAL INDEX KEY: 0001586835 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 161932047 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2016-10-06 0 0001280600 ACCELERON PHARMA INC XLRN 0001586835 Kumar Ravindra 128 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 SVP & Chief Scientific Officer Common Stock 2016-10-06 4 M 0 7124 5.28 A 91875 D Common Stock 2016-10-06 4 S 0 14448 34.31 D 77427 D Common Stock 2016-10-06 4 S 0 1561 34.98 D 75866 D Common Stock 2016-10-07 4 M 0 954 3.88 A 76820 D Common Stock 2016-10-07 4 M 0 10984 5.28 A 87804 D Common Stock 2016-10-07 4 M 0 1115 5.28 A 88919 D Common Stock 2016-10-07 4 M 0 2381 7.12 A 91300 D Common Stock 2016-10-07 4 M 0 4210 24.11 A 95510 D Common Stock 2016-10-07 4 S 0 19616 33.37 D 75894 D Common Stock 2016-10-07 4 S 0 28 34 D 75866 D Common Stock 2016-10-10 4 M 0 4182 7.12 A 80048 D Common Stock 2016-10-10 4 M 0 8101 24.11 A 88149 D Common Stock 2016-10-10 4 M 0 4550 27.97 A 92699 D Common Stock 2016-10-10 4 S 0 16833 34.14 D 75866 D Option to Purchase Common Stock 5.28 2016-10-06 4 M 0 7124 0 D 2022-06-07 Common Stock 7124 17876 D Option to Purchase Common Stock 3.88 2016-10-07 4 M 0 954 0 D 2020-12-02 Common Stock 954 4561 D Option to Purchase Common Stock 5.28 2016-10-07 4 M 0 10984 0 D 2021-12-16 Common Stock 10984 0 D Option to Purchase Common Stock 5.28 2016-10-07 4 M 0 1115 0 D 2022-06-07 Common Stock 1115 16761 D Option to Purchase Common Stock 7.12 2016-10-07 4 M 0 2381 0 D 2022-12-12 Common Stock 2381 5119 D Option to Purchase Common Stock 24.11 2016-10-07 4 M 0 4210 0 D 2023-12-05 Common Stock 4210 24790 D Option to Purchase Common Stock 7.12 2016-10-10 4 M 0 4182 0 D 2022-12-12 Common Stock 4182 937 D Option to Purchase Common Stock 24.11 2016-10-10 4 M 0 8101 0 D 2023-12-05 Common Stock 8101 16689 D Option to Purchase Common Stock 27.97 2016-10-10 4 M 0 4550 0 D 2026-03-03 Common Stock 4550 31850 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.84 to $34.80 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.82 to $35.25 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.89 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.42 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant. The options of registrant's common stock vest in equal quarterly installments over the four years after January 1, 2016. /s/ John D. Quisel, as attorney-in-fact for Ravindra Kumar 2016-10-11